<- Go Home
Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Market Cap
KRW 70.1T
Volume
56.2K
Cash and Equivalents
KRW 520.4B
EBITDA
KRW 2.8T
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
KRW 2.6T
Profit Margin
54.86%
52 Week High
KRW 2.0M
52 Week Low
KRW 1.2M
Dividend
N/A
Price / Book Value
8.85
Price / Earnings
57.89
Price / Tangible Book Value
8.93
Enterprise Value
KRW 69.6T
Enterprise Value / EBITDA
24.81
Operating Income
KRW 2.2T
Return on Equity
18.25%
Return on Assets
9.43
Cash and Short Term Investments
KRW 1.7T
Debt
KRW 1.2T
Equity
KRW 7.9T
Revenue
KRW 4.8T
Unlevered FCF
KRW 1.1T
Sector
Life Sciences Tools and Services
Category
N/A